Broad spectrum MMP inhibitor (IC50
values are 0.7, 0.9, 13, 16 and 1170 nM for MMP-2, MMP-13, MMP-9, MMP-3 and MMP-1 respectively). Attenuates early left ventricular dilation after experimental myocardial infarction in mice.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from Pfizer Inc.
Matrix metalloproteinease inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice.
Rohde et al.
Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction.
Lindsey et al.
Differences in inflammation, MMP activation and collagen damage account for gender difference in murine cardiac rupture following myocardial infarction.
Fang et al.
The citations listed below are publications that use Tocris products. Selected citations for CP 471474 include:
Showing Results 1 - 2 of 2